Cargando…

Toxicogenomic Biomarkers for Liver Toxicity

Toxicogenomics (TGx) is a widely used technique in the preclinical stage of drug development to investigate the molecular mechanisms of toxicity. A number of candidate TGx biomarkers have now been identified and are utilized for both assessing and predicting toxicities. Further accumulation of novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiyosawa, Naoki, Ando, Yosuke, Manabe, Sunao, Yamoto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Toxicologic Pathology 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246017/
https://www.ncbi.nlm.nih.gov/pubmed/22271975
http://dx.doi.org/10.1293/tox.22.35
_version_ 1782219916489785344
author Kiyosawa, Naoki
Ando, Yosuke
Manabe, Sunao
Yamoto, Takashi
author_facet Kiyosawa, Naoki
Ando, Yosuke
Manabe, Sunao
Yamoto, Takashi
author_sort Kiyosawa, Naoki
collection PubMed
description Toxicogenomics (TGx) is a widely used technique in the preclinical stage of drug development to investigate the molecular mechanisms of toxicity. A number of candidate TGx biomarkers have now been identified and are utilized for both assessing and predicting toxicities. Further accumulation of novel TGx biomarkers will lead to more efficient, appropriate and cost effective drug risk assessment, reinforcing the paradigm of the conventional toxicology system with a more profound understanding of the molecular mechanisms of drug-induced toxicity. In this paper, we overview some practical strategies as well as obstacles for identifying and utilizing TGx biomarkers based on microarray analysis. Since clinical hepatotoxicity is one of the major causes of drug development attrition, the liver has been the best documented target organ for TGx studies to date, and we therefore focused on information from liver TGx studies. In this review, we summarize the current resources in the literature in regard to TGx studies of the liver, from which toxicologists could extract potential TGx biomarker gene sets for better hepatotoxicity risk assessment.
format Online
Article
Text
id pubmed-3246017
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher The Japanese Society of Toxicologic Pathology
record_format MEDLINE/PubMed
spelling pubmed-32460172012-01-23 Toxicogenomic Biomarkers for Liver Toxicity Kiyosawa, Naoki Ando, Yosuke Manabe, Sunao Yamoto, Takashi J Toxicol Pathol Review Toxicogenomics (TGx) is a widely used technique in the preclinical stage of drug development to investigate the molecular mechanisms of toxicity. A number of candidate TGx biomarkers have now been identified and are utilized for both assessing and predicting toxicities. Further accumulation of novel TGx biomarkers will lead to more efficient, appropriate and cost effective drug risk assessment, reinforcing the paradigm of the conventional toxicology system with a more profound understanding of the molecular mechanisms of drug-induced toxicity. In this paper, we overview some practical strategies as well as obstacles for identifying and utilizing TGx biomarkers based on microarray analysis. Since clinical hepatotoxicity is one of the major causes of drug development attrition, the liver has been the best documented target organ for TGx studies to date, and we therefore focused on information from liver TGx studies. In this review, we summarize the current resources in the literature in regard to TGx studies of the liver, from which toxicologists could extract potential TGx biomarker gene sets for better hepatotoxicity risk assessment. The Japanese Society of Toxicologic Pathology 2009-04-06 2009-03 /pmc/articles/PMC3246017/ /pubmed/22271975 http://dx.doi.org/10.1293/tox.22.35 Text en ©2009 The Japanese Society of Toxicologic Pathology http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
spellingShingle Review
Kiyosawa, Naoki
Ando, Yosuke
Manabe, Sunao
Yamoto, Takashi
Toxicogenomic Biomarkers for Liver Toxicity
title Toxicogenomic Biomarkers for Liver Toxicity
title_full Toxicogenomic Biomarkers for Liver Toxicity
title_fullStr Toxicogenomic Biomarkers for Liver Toxicity
title_full_unstemmed Toxicogenomic Biomarkers for Liver Toxicity
title_short Toxicogenomic Biomarkers for Liver Toxicity
title_sort toxicogenomic biomarkers for liver toxicity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246017/
https://www.ncbi.nlm.nih.gov/pubmed/22271975
http://dx.doi.org/10.1293/tox.22.35
work_keys_str_mv AT kiyosawanaoki toxicogenomicbiomarkersforlivertoxicity
AT andoyosuke toxicogenomicbiomarkersforlivertoxicity
AT manabesunao toxicogenomicbiomarkersforlivertoxicity
AT yamototakashi toxicogenomicbiomarkersforlivertoxicity